Acute Kidney Injury Therapeutics Pipeline Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Acute Kidney Injury Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.

The study analyzed that AKI therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.

According to the research findings, a majority of the drug candidates for the treatment of AKI are being developed to be administered by the intravenous route. It has been observed that the drugs which are being administered through intravenous route have high efficacy because of their higher bioavailability.

Various health organizations such as National Institute of Diabetes and Digestive and Kidney Diseases and Small Business Innovation Research (SBIR) program of the U.S. Small Business Administration (SBA) are strengthening the growth of AKI therapeutics pipeline. For instance, TheraSource LLC received a funding of $335,318 from SBIR for its research project aimed at demonstrating the feasibility of developing recombinant human milk fat globule epidermal growth factor rhMFG E, as a novel and effective therapeutic for treating patients suffering with AKI, associated with ischemia due to low renal perfusion.

There has been an increase in the number of patents approved for the development of drug candidates for the treatment of AKI. For instance, in October 2016, the USPTO issued U.S. Patent 9,464,114 to Arch BioPartners, entitled, Peptides that Block Leukocyte Recruitment and Methods of Use. This was the first patent issued protecting the composition and method of use for Metablok.

Most of the companies are developing innovative technologies for the synthesis or production of drug candidates for the treatment of AKI. For instance, Quark Pharmaceuticals Inc. is using an innovative technology platform for generation of chemically modified siRNA compounds and their delivery to the desired organs. Also, Silver Creek Pharmaceuticals Inc. is using smart growth factor technology platform for the development of growth factors that play an important role in development, maintenance of tissue homeostasis, and pathology of many disease states.

Some of the key players involved in the development of AKI therapeutics include Alloksys Life Sciences B.V., Stealth BioTherapeutics Inc., and Angion Biomedica Corp.

For more information about this report visit https://www.researchandmarkets.com/research/495v3r/acute_kidney?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Liver and Kidney Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Liver and Kidney Disorders Drugs